Executive interview – VolitionRX reports their Full Year 2017 Earnings

Executive interview – VolitionRX reports their Full Year 2017 Earnings

VolitionRx Limited (VNRX:US), a multi-national life sciences company developing simple, easy to use blood-based cancer tests, today announced its Full Year 2017 earnings and will discuss this news as well as a business update on a conference call this morning. The company this week also announced interim results from a 680-Subject Clinical Trial in Colorectal Cancer.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free